Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Stopped Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.

Conditions

• Chronic Hepatitis B

Interventions

• DRUG: Inarigivir Soproxil
• DRUG: TAF

Sponsor

Gilead Sciences

Collaborators

• [object Object]